Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 16/20 | 0.41 |
| ▸ | PIK3R1 | P27986 | 7/20 | 0.40 |
| ▸ | MTOR | P42345 | 2/20 | 0.39 |
| ▸ | BACE1 | P56817 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16164495 | 0.86 | PIK3CA (0.44) | ALDH1A1PIK3CAPIK3R1MTORMEN1 | |
| SCHEMBL19783077 | 0.84 | NPSR1 (0.44) | PIK3CAPIK3R1MTORBACE1 | |
| SCHEMBL29454955 | 0.81 | SMN1; SMN2 (0.51) | SMN1; SMN2PIK3CA | |
| SCHEMBL31348095 | 0.81 | SMN1; SMN2 (0.48) | SMN1; SMN2PIK3CAPIK3R1 | |
| SCHEMBL14923559 | 0.80 | SYK (0.46) | PIK3CAPIK3R1MTOR | |
| SCHEMBL25200798 | 0.79 | TSHR (0.45) | SMN1; SMN2 | |
| SCHEMBL18839498 | 0.78 | GAA (0.45) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL16562090 | 0.77 | PIK3CA (0.39) | PIK3CAPIK3R1MTOR | |
| Hydrochloric Acid SCHEMBL16554436 | 0.77 | PIK3CA (0.44) | PIK3CAPIK3R1MTOR | |
| SCHEMBL30151852 | 0.76 | NNMT (0.49) | PIK3CA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250034141-A1 | HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2025-01-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250034141-A1 | HETEROCYCLIC COMPOUND | MALT1, SQSTM1, PPM1D | ALDH1A1 1199/4885SMN1; SMN2 2190/4885PIK3CA 2309/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.